← Back to Search

⁸⁹Zr-Df-IAB22M2C for Positron Emission Tomography (iCorrelate Trial)

Phase 2
Waitlist Available
Research Sponsored by ImaginAb, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

iCorrelate Trial Summary

This study is evaluating whether a radioactive tracer may help detect cancer cells in the body.

Eligible Conditions
  • Positron Emission Tomography
  • Metastatic Tumor

iCorrelate Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
12-Lead electrocardiogram
ALP laboratory values
ALT laboratory values
+25 more
Secondary outcome measures
Assessment of Baseline and On-treatment ⁸⁹Zr-Df-IAB22M2C uptake and distribution in tumors and lymphoid organs, and measurement of change between the paired observations
Description of biodistribution patterns of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) on PETbaseline and PETTx and any changes in biodistribution between baseline and On-Treatment.
Measurement of change in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in biopsied tumors as determined by SUV-based quantitative analysis
Other outcome measures
Assessment of changes in ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake and distribution from baseline to 5-7 days start of immunotherapy if available.
Correlation of the 89Zr-Df-IAB22M2C(CD8 PET Tracer) uptake on a subset of PETbaseline and PETtx scans that have been virtually reconstructed with lower theoretical doses of 8⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) with CD8+ T cells from IHC analysis.
Correlation of visual and quantitative ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) uptake in tumor lesions with change in CD8+ T cells as determined by IHC from biopsy samples obtained prior to and 4 to 7 weeks after the start of immunotherapy.
+5 more

iCorrelate Trial Design

1Treatment groups
Experimental Treatment
Group I: ⁸⁹Zr-Df-IAB22M2C InfusionExperimental Treatment1 Intervention
A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
⁸⁹Zr-Df-IAB22M2C
2018
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

ImaginAb, Inc.Lead Sponsor
12 Previous Clinical Trials
248 Total Patients Enrolled
Ron Korn, MD, PhDStudy DirectorImaginAb, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
2018. "⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03802123.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top